KSQ Therapeutics CEO and leadership

Qasim Rizvi is the Senior Vice President of Operations and Chief Commercial Officer at Kiniksa Pharmaceuticals.

David Meeker, 57, was appointed CEO of Genzyme in October 2011. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions. As Chief Operating Officer, he played an important role in the integration with Sanofi. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®. Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. Dr. Meeker is a Board member of BIO, the Biotechnology Industry Organization. He is also a Board member of Prize4Life, an organization dedicated to accelerating the discovery of treatments for amyotrophic lateral sclerosis; the California Institute of Healthcare (CHI), an independent organization devoted to researching and advocating policy to forward the interests of California’s biomedical community; and Savient Pharmaceuticals, a specialty biopharmaceutical company focused on developing and commercializing a treatment for chronic gout. Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Frank Stegmeier is a Chief Scientific Officer at KSQ Therapeutics Inc and Board Member at Addgene and is based in Acton, Massachusetts. He has worked as Head of Oncology Target Discovery at Novartis and Postdoctoral Fellow at Harvard Medical School. Frank attended Massachusetts Institute of Technology (MIT) between 1999 and 2004, Eberhard Karls Universität Tübingen between 1996 and 1999, and Harvard University between 2004 and 2007.

Qasim Rizvi is the Senior Vice President of Operations and Chief Commercial Officer at Kiniksa Pharmaceuticals.

David Meeker, 57, was appointed CEO of Genzyme in October 2011. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions. As Chief Operating Officer, he played an important role in the integration with Sanofi. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®. Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. Dr. Meeker is a Board member of BIO, the Biotechnology Industry Organization. He is also a Board member of Prize4Life, an organization dedicated to accelerating the discovery of treatments for amyotrophic lateral sclerosis; the California Institute of Healthcare (CHI), an independent organization devoted to researching and advocating policy to forward the interests of California’s biomedical community; and Savient Pharmaceuticals, a specialty biopharmaceutical company focused on developing and commercializing a treatment for chronic gout. Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.